Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

Disease Characteristics: Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma Measurable lesion diagnosed by CT scan Recurrent/metastatic disease considered surgically unresectable. Prior/Concurrent Therapy: Chemotherapy: Patients who either have failed at least one regimen of standard systemic therapy, or are clinically asymptomatic and are not presently being considered for chemotherapy (Enrollment must occur at least 4 weeks beyond last treatment) Other: Prior treatment with investigational agents is excluded unless follow-up is completed and patient is off study Patient Characteristics/Inclusion Criteria: Performance Status: Patients with a Karnofsky performance status > 70% (or equivalent, ECOG 0-1) and expected survival of at least 3 months. Hematopoietic: WBC >/= 3000 mm3, neutrophils >/= 1500 mm3, platelets >/= 75,000, CEA < 300 ng/mL Hepatic: Serum bilirubin </= 2.0 mg/dL, ALT < 2.5 x IULN Cardiovascular: Patients with LVEF >/= 40% by required MUGA/2D-ECHO study. Pulmonary: Patients with FEV1 >/= 60% by required Pulmonary Function Tests Other: Patients agreeing to use a medically effective method of contraception during and for a period of 3 months after the treatment period. A pregnancy test will be preformed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent. Patients with a significant concurrent medical condition that could affect the patient's ability to tolerate or complete the study.